Back to discover
Drug

Captopril

Established medicine
ClassAngiotensin-converting enzyme inhibitorResearchOngoing clinical research
Also known as CP, Capoten, Captopril-Hydrochlorothiazide, D-2-methyl-3-mercaptopropanoyl-L-proline+3 more

CP, Capoten, Captopril-Hydrochlorothiazide, D-2-methyl-3-mercaptopropanoyl-L-proline, D-3-mercapto-2-methylpropanoyl-L-proline, L-Captopril, Captoprilum.

2
Research papers
2
Active clinical trials
Angiotensin-converting enzyme
Primary target
Latest activity
beta

Recent clinical, regulatory, research and industry developments relating to this drug.

Profile

Identifiers & mechanism

Canonical identifiers, marketed brand names and mechanism, resolved across RxNorm, ChEMBL and ATC.

Canonical name
Captopril
Aliases & brands
CPCapotenCaptopril-HydrochlorothiazideD-2-methyl-3-mercaptopropanoyl-L-prolineD-3-mercapto-2-methylpropanoyl-L-prolineL-CaptoprilCaptoprilum
RxNorm CUI
1998
ChEMBL ID
CHEMBL1560
ATC codes
C09AA01
UNII
9G64RSX1XD
Primary mechanism
Angiotensin-converting enzyme inhibitor

Pharmacology & targets

1 target

Known molecular targets and mechanisms supported by curated pharmacology databases.

INHIBITORAngiotensin-converting enzyme inhibitor

Clinical trials

28 trials

The current development programme across all trial phases — status mix, phase distribution and the late-stage studies shaping the evidence base.

Development programme
CLINICALTRIALS.GOV · LIVE REGISTRY
28
registered trials across all phases
LATEST COMPLETION 2025
2
Active studies
1
Recruiting
14
Late-stage (III+)
12
Completed
14
Discontinued
PHASE DISTRIBUTIONn = 28
Early Phase 11Phase 15Phase 1 / 24Phase 24Phase 2 / 31Phase 33Phase 48Phase N / A2

Late-stage studies

Phase III+ trials still open or recently active — where late-stage evidence is being generated.

Recent completions

Trials that read out recently, adding to the completed evidence base.

Research activity

2 papers

Key research shaping understanding of this drug, combining the latest publications with the most influential evidence.

Publications over time
20032004
Major research themes2
Angiotensin II Type 1 Receptor Blockers1Angiotensin Receptor Antagonists1
Journals, researchers & institutions
Top journals
  • The New England journal of medicine2
Leading researchers
  • Califf RM2
  • Leimberger JD2
  • McMurray JJ2
  • Pfeffer MA2
  • Rouleau JL2
  • Solomon SD2
  • Velazquez EJ2
  • Zelenkofske S2
Leading institutions
free-text, unnormalised
  • Brigham and Women's Hospital2

Related diseases

2 conditions

Regulator-approved indications and conditions co-mentioned with this drug across the research literature. Number shows shared papers.

Related drugs

2 matches

Drugs sharing diseases, protein targets and literature with this one. Ranked by graph evidence (shared targets + diseases weighted above co-mentions).

Studied across 6 of the same disease areas as Captopril in the shared literature.

6 shared diseases2 shared papers

Studied across 6 of the same disease areas as Captopril in the shared literature.

6 shared diseases2 shared papers
References & data sources
  • RxNorm (U.S. National Library of Medicine) — drug identity
  • ChEMBL (EMBL-EBI) & UniProt — pharmacology and targets
  • Europe PMC — research literature
  • ClinicalTrials.gov — clinical trials